ClinicalTrials.gg
CompletedNCT00539006Updated Dec 9, 2016Results posted

Comparator Study Evaluating Patient Preference Of FFNS vs. FPNS

A Phase 4 interventional study of FPNS and FFNS in Rhinitis, Allergic, Perennial, sponsored by GlaxoSmithKline. Completed at 24 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-09.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
377
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 21 studies testing fluticasone in Rhinitis, Allergic, Perennial — 1 open to participants now, 1 under way, none of them phase 3. Fluticasone · Rhinitis, Allergic, Perennial.

Enrollment
6th of 21
377 · median 288
Started
2007
with 3 others
Phase 4
7 of 21
1 open now
Registered
11th of 21
by date
Lead sponsor
18 of 21
GlaxoSmithKline

Among the 21 studies testing fluticasone in Rhinitis, Allergic, Perennial, this one is the 6th largest by enrollment, is one of 4 that started in 2007, is one of 7 in phase 4, and was the 11th registered.

Rhinitis, Allergic, Perennial

178 studies on the registry are indexed under Rhinitis, Allergic, Perennial; 9 are open to participants now.

Browse Rhinitis, Allergic, Perennial studies →

Open to participants now

1 of the 21 studies testing fluticasone in Rhinitis, Allergic, Perennial is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 3 Rhinitis, Allergic, Perennial studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing fluticasone in Rhinitis, Allergic, Perennial, or all of them as a file.
02

Study summary

The purpose of this replicate study to FFU105927 is to provide data on subject preference of FFNS as compared with FPNS.

Read the detailed description

A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, One-Week, Cross-Over, Multicenter Study to Evaluate the Efficacy, Patient Preference and Experience of One-Daily, Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200mcg Fluticasone Propionate Nasal Spray in Adult Subjects with Seasonal Allergic Rhinitis (FFU105924)

03

Conditions studied

  • Rhinitis, Allergic, Perennial

Keywords

  • fluticasone propionate
  • seasonal allergic rhinitis
  • fluticasone furoate
  • experience
  • GW685698X
  • preference
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has provided an appropriately signed and dated informed consent.
  • Otherwise healthy outpatient with fall allergy
  • Subject is treatable on an outpatient basis.
  • Age
  • 18 years or age or older at time of Visit 2
  • Male or eligible female
  • Female subjects should not be enrolled if they plan to become pregnant during the time of study participation. A urine pregnancy test will be required of all females at all visits to determine if the subject is pregnant.
  • To be eligible for entry into the study, females of must commit to the consistent and correct use of an acceptable method of , as defined by the following:
  • Abstinence
  • Females of childbearing potential who are not sexually active must commit to complete abstinence from intercourse for two weeks before exposure to the study drug, throughout the clinical trial, and for a period after the trial to account for elimination of the drug (minimum of six days).
  • Oral contraceptive (either combined estrogen/progestin or progestin only)
  • Injectable progestogen
  • Implants of levonorgestrel
  • Percutaneous contraceptive patches
  • Intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate of less than 1% per year,
  • Male partner who is sterile (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study and is the sole sexual partner for that female subject
  • Double barrier method-condom or occlusive cap (diaphragm or cervical /vault caps) plus spermicide
  • Estrogenic vaginal ring
  • Diagnosis of SAR
  • SAR is defined as follows:
  • A clinical history (written or verbal) of SAR with seasonal allergy symptoms (nasal symptoms) during each of the last two fall allergy seasons, and
  • A positive skin test (by prick method) to fall allergen prevalent to the geographic area during the conduct of the study, within 12 months prior to Visit 1 or at Visit 1.
  • A positive skin test is defined as a wheal 3 mm larger than the diluent control for prick testing.
  • In vitro tests for specific IgE (such as RAST, PRIST) will not be allowed as a diagnosis of SAR.
  • Subjects who meet the above criteria and who may also have perennial allergic rhinitis or vasomotor rhinitis are eligible for randomization.
  • Adequate exposure to seasonal pollen
  • Subject resides within a geographical region where exposure to fall seasonal allergen is expected to be significant during the entire study period.
  • Subject does not plan to travel outside this area for more than 48 hours of the study period.
  • Ability to comply with study procedures
  • Subject understands and is willing, able and likely to comply with study procedures and restrictions.
  • Literate
  • Subject must be able to read, comprehend, and record information in English

Exclusion criteria

Exclusion Criteria:

  • Recent use (less than 1 year) of using branded (FLONASE) or generic FPNS or use of FFNS (VERAMYST).
  • Significant concomitant medical conditions, defined as but not limited to:
  • A historical or current evidence of uncontrolled disease of any body system (e.g., tuberculosis, psychological disorders, eczema). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through study participation or which would confound the interpretation of the study results if the disease/condition exacerbated during the study.
  • A severe physical obstruction of the nose (e.g., deviated septum or nasal polyp) or nasal septal perforation that could affect the deposition of intranasal study drug
  • Nasal (eg, nasal septum) injury or surgery in the last 3 months
  • Asthma, with the exception of mild intermittent asthma [National Asthma Education and Prevention Program (NARPP) Guidelines, 2002].
  • Rhinitis medicamentosa
  • Bacterial or viral infection (e.g., common cold) of the eyes or upper respiratory tract within two weeks of Visit 1 or during the screening period
  • Documented evidence of acute or significant chronic sinusitis, as determined by the individual investigator
  • Current or history of glaucoma and/or cataracts or ocular herpes simplex
  • Physical impairment that would affect subject's ability to participate safely and fully in the study
  • Clinical evidence of a Candida infection of the nose
  • History of psychiatric disease, intellectual deficiency, poor motivation, substance abuse (including drug and alcohol) or other conditions that will limit the validity of or that would confound the interpretation of the study results
  • History of adrenal insufficiency
  • History of shingles
  • Chickenpox or measles: A subject is not eligible if he/she currently has chickenpox or measles, or has been exposed to chickenpox or measles during the last 3 weeks and is non-immune. If a subject develops chickenpox or measles during the study, he/she will be withdrawn from the study. If a non-immune subject is exposed to chickenpox or measles during the study, his/her continuation in the study will be at the discretion of the investigator, taking into consideration the likelihood of developing active disease.
  • Use of other , defined as:
  • Intranasal corticosteroid within four weeks prior to Visit 1.
  • Inhaled, oral, intramuscular, intravenous, ocular, and/or dermatological corticosteroid (with the exception of hydrocortisone cream/ointment, 1% or less) within eight weeks prior to Visit 1.
  • Use of other allergy medications within the timeframe indicated relative to Visit 1
  • Intranasal cromolyn within 14 days prior to Visit 1
  • Short-acting prescription and OTC antihistamines, including antihistamines contained in insomnia and 'nighttime' pain formulations taken for insomnia, within 3 days prior to Visit 1
  • Long-acting antihistamines within 10 days prior to Visit 1: loratadine, desloratadine, fexofenadine, cetirizine
  • Oral or intranasal decongestants within 3 days prior to Visit 1
  • Intranasal, oral, or inhaled anticholinergics within 3 days prior to Visit 1
  • Oral antileukotrienes within 3 days prior to Visit 1
  • Subcutaneous omalizumab (Xolair) within 5 months of Visit 1
  • Intranasal antihistamines (e.g. Astelin) within 2 weeks prior to Visit 1
  • Use of other medications that may affect allergic rhinitis or its symptoms
  • Chronic use of concomitant medications, such as tricyclic antidepressants, that would affect assessment of the effectiveness of the study drug
  • Chronic use of long-acting beta-agonists (e.g., salmeterol)
  • Chronic use of other intranasally administered medications (e.g., calcitonin-salmon)
  • Nasal irrigation solutions
  • Use of medications 8 weeks prior to screening and during the study
  • Use of any medications that significantly inhibit the cytochrome P450 subfamily enzyme , including ritonavir and ketoconazole
  • Immunotherapy
  • Subjects may be enrolled into the study if the immunotherapy was not initiated within 30 days of Visit 1, if the dose has remained fixed over the 30 days prior to Visit 1, and the dose will remain fixed for the duration of the study.
  • Allergy/Intolerance
  • Known to corticosteroids or any in the product
  • Clinical trial/experimental medication experience
  • Has recent exposure to an study drug within 30 days of Visit 1
  • Participation in a previous or current GSK FFNS study
  • Positive or inconclusive pregnancy test or female who is breastfeeding
  • Has a positive or inconclusive pregnancy test at Visit 1 or Visit 2
  • Affiliation with investigational site
  • Subject is a participating investigator, sub-investigator, study co-ordinator, or employee of a participating investigator, or is an immediate family member of the aforementioned.
  • Current tobacco use
  • Subject currently uses smoking products including cigarettes, cigars, and pipe or chewing tobacco.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
377 participants (actual)

Study arms

  • Active comparator
    FFNS, FPNS

    active compound

    Drug: FPNS · Drug: FFNS

  • Active comparator
    FPNS, FFNS

    active compound

    Drug: FPNS · Drug: FFNS

  • Placebo comparator
    placebo FFNS, placebo FPNS

    placebo arm

    Drug: placebo FPNS · Drug: placebo FFNS

  • Placebo comparator
    placebo FPNS, placebo FFNS

    placebo arm

    Drug: placebo FPNS · Drug: placebo FFNS

Interventions

  • DrugFPNS

    fluticasone propionate nasal spray

    Also known as: fluticasone propionate, fluticasone furoate

  • DrugFFNS

    fluticasone furoate nasal spray

  • Drugplacebo FPNS

    placebo nasal spray matching fluticasone propionate nasal spray

  • Drugplacebo FFNS

    placebo nasal spray matching fluticasone furoate nasal spray

06

What researchers measure

Primary outcomes

  1. Comparison of Mean Change From Baseline in Daily Reflective Total Nasal Symptom Score (rTNSS) Over Treatment Periods of Active Drug Nasal Sprays Versus Placebos

    Reflective Total Nasal Symptom scores (rTNSS) symptoms of rhinorrhea, nasal congestion, nasal itching, sneezing using scale of: 0=none, 1=mild, 2=moderate, 3=severe; maximum score=12. The mean of AM and PM scores were used.

    Time frame: Baseline, Treatment Period 1 (Days 1-7), Treatment Period 2 (Days 15-21)

  2. Participant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Scent/Odor

    Participants assessed preference of scent/odor for the nasal sprays used during the treatment periods by answering "I prefer product 1" for spray used during Treatment Period 1 or "I prefer product 2" for spray used during Treatment Period 2. Participant could also choose "I have no preference."

    Time frame: End of Crossover Period (Day 22)

Secondary outcomes

  1. Participant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Leaking Out of Nose/Down Throat

    Participants assessed preference over leaking out of nose/down throat for the nasal sprays used during the treatment periods by answering "I prefer product 1" for spray used during Treatment Period 1 or "I prefer product 2" for spray used during Treatment Period 2. Participant could also choose "I have no preference."

    Time frame: End of Crossover Period (Day 22)

  2. Participant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Ease of Use

    Participants assessed preference over ease of use for the nasal sprays used during the treatment periods by answering "I prefer product 1" for spray used during Treatment Period 1 or "I prefer product 2" for spray used during Treatment Period 2. Participant could also choose "I have no preference."

    Time frame: End of Crossover Period (Day 22)

  3. Participant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Gentleness of Mist

    Participants assessed preference over gentleness of mist for the nasal sprays used during the 2 treatment periods

    Time frame: End of Crossover Period (Day 22)

  4. Comparision of Mean Change From Baseline Over Treatment Periods in Daytime Reflective Total Nasal Symptom Scores (D r-TNSS) for Active Drug Nasal Sprays Versus Placebos

    Reflective Total Nasal Symptom scores (rTNSS) symptoms of rhinorrhea, nasal congestion, nasal itching, sneezing using scale of: 0=none, 1=mild, 2=moderate, 3=severe.

    Time frame: Baseline, Treatment Period 1 (Days 1-7), Treatment Period 2 (Days 15-21)

  5. Comparision of Mean Change From Baseline Over Treatment Periods in Nighttime Reflective Total Nasal Symptom Scores (N-rTNSS) for Active Drug Nasal Sprays Versus Placebos

    Reflective Total Nasal Symptom scores (rTNSS) symptoms of rhinorrhea, nasal congestion, nasal itching, sneezing using scale of: 0=none, 1=mild, 2=moderate, 3=severe; maximum score=12.

    Time frame: Baseline, Treatment Period 1 (Days 1-7), Treatment Period 2 (Days 15-21)

07

Results

Posted Sep 30, 2009

Participant flow

Pre-treatment
Participant flow — Pre-treatment
MilestoneFluticasone Furoate NS/Fluticasone Propionate NSPlacebo - FF/FPFluticasone Propionate NS/Fluticasone Furoate NSPlacebo - FP/FF
Started96959591
Completed96949591
Not completed0100
Withdrew: Other0100
Treatment Period 1
Participant flow — Treatment Period 1
MilestoneFluticasone Furoate NS/Fluticasone Propionate NSPlacebo - FF/FPFluticasone Propionate NS/Fluticasone Furoate NSPlacebo - FP/FF
Started96949591
Completed96949390
Not completed0021
Withdrew: Lost to follow-up0010
Withdrew: Protocol violation0010
Withdrew: Lack of efficacy0001
Washout
Participant flow — Washout
MilestoneFluticasone Furoate NS/Fluticasone Propionate NSPlacebo - FF/FPFluticasone Propionate NS/Fluticasone Furoate NSPlacebo - FP/FF
Started96949390
Completed76847781
Not completed2010169
Withdrew: Adverse event2100
Withdrew: Protocol violation1100
Withdrew: Withdrawal by subject0200
Withdrew: Failed to meet continuation criteria165146
Withdrew: Other1123
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneFluticasone Furoate NS/Fluticasone Propionate NSPlacebo - FF/FPFluticasone Propionate NS/Fluticasone Furoate NSPlacebo - FP/FF
Started76847781
Completed75837781
Not completed1100
Withdrew: Protocol violation1000
Withdrew: Other0100
Post-Study
Participant flow — Post-Study
MilestoneFluticasone Furoate NS/Fluticasone Propionate NSPlacebo - FF/FPFluticasone Propionate NS/Fluticasone Furoate NSPlacebo - FP/FF
Started75837781
Completed75837781
Not completed0000

Outcome measures

SecondaryParticipant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Leaking Out of Nose/Down Throat

Participants assessed preference over leaking out of nose/down throat for the nasal sprays used during the treatment periods by answering "I prefer product 1" for spray used during Treatment Period 1 or "I prefer product 2" for spray used during Treatment Period 2. Participant could also choose "I have no preference."

Time frame:
End of Crossover Period (Day 22)
Reported as:
Number · Participants
Participant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Leaking Out of Nose/Down Throat
ParticipantsFluticasone Furoate NS/Fluticasone Propionate NSFluticasone Propionate NS/Fluticasone Furoate NSTotal
Preferred - Fluticasone Furoate Nasal Spray434689
Preferred - Fluticasone Propionate Nasal Spray151732
No Preference191433
SecondaryParticipant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Ease of Use

Participants assessed preference over ease of use for the nasal sprays used during the treatment periods by answering "I prefer product 1" for spray used during Treatment Period 1 or "I prefer product 2" for spray used during Treatment Period 2. Participant could also choose "I have no preference."

Time frame:
End of Crossover Period (Day 22)
Reported as:
Number · Participants
Participant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Ease of Use
ParticipantsFluticasone Furoate NS/Fluticasone Propionate NSFluticasone Propionate NS/Fluticasone Furoate NSTotal
Preferred - Fluticasone Furoate Nasal Spray192847
Preferred - Fluticasone Propionate Nasal Spray423779
No Preference161228
PrimaryComparison of Mean Change From Baseline in Daily Reflective Total Nasal Symptom Score (rTNSS) Over Treatment Periods of Active Drug Nasal Sprays Versus Placebos

Reflective Total Nasal Symptom scores (rTNSS) symptoms of rhinorrhea, nasal congestion, nasal itching, sneezing using scale of: 0=none, 1=mild, 2=moderate, 3=severe; maximum score=12. The mean of AM and PM scores were used.

Time frame:
Baseline, Treatment Period 1 (Days 1-7), Treatment Period 2 (Days 15-21)
Reported as:
Mean · Scores on a scale
Comparison of Mean Change From Baseline in Daily Reflective Total Nasal Symptom Score (rTNSS) Over Treatment Periods of Active Drug Nasal Sprays Versus Placebos
Scores on a scaleFluticasone Furoate NS/Fluticasone Propionate NSPlacebo - FF/FPFluticasone Propionate NS/Fluticasone Furoate NSPlacebo - FP/FF
Change from Baseline Treatment Period One-2.7 ± 0.29-1.5 ± 0.20-2.4 ± 0.24-1.6 ± 0.22
Change from Baseline Treatment Period Two-2.5 ± 0.29-1.9 ± 0.24-2.7 ± 0.27-1.7 ± 0.21
Statistical analysis
  • Fluticasone Furoate NS/Fluticasone Propionate NS vs Placebo - FF/FP · ANCOVA · p = <0.001 · Mean difference (net): -1.1 · 95% CI -1.5 to -0.6Mean Difference = Mean Change in FFNS - Mean Change in Placebo
  • Fluticasone Propionate NS/Fluticasone Furoate NS vs Placebo - FP/FF · ANCOVA · p = 0.004 · Mean difference (net): -0.6 · 95% CI -1.1 to -0.2Mean Difference = Mean Change in FPNS - Mean Change in Placebo
PrimaryParticipant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Scent/Odor

Participants assessed preference of scent/odor for the nasal sprays used during the treatment periods by answering "I prefer product 1" for spray used during Treatment Period 1 or "I prefer product 2" for spray used during Treatment Period 2. Participant could also choose "I have no preference."

Time frame:
End of Crossover Period (Day 22)
Reported as:
Number · Participants
Participant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Scent/Odor
ParticipantsFluticasone Furoate NS/Fluticasone Propionate NSFluticasone Propionate NS/Fluticasone Furoate NSTotal
Preferred - Fluticasone Furoate Nasal Spray434184
Preferred - Fluticasone Propionate Nasal Spray211738
No Preference131932
Statistical analysis
  • Fluticasone Furoate NS/Fluticasone Propionate NS vs Fluticasone Propionate NS/Fluticasone Furoate NS · Cochran-Mantel-Haenszel · p = <0.001Cochran-Mantel-Haenszel(CMH): stratified approximation to Prescotts test; variation of chi-square test for treatment sequence/subjects no preference.
SecondaryParticipant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Gentleness of Mist

Participants assessed preference over gentleness of mist for the nasal sprays used during the 2 treatment periods

Time frame:
End of Crossover Period (Day 22)
Reported as:
Number · Participants
Participant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Gentleness of Mist
ParticipantsFluticasone Furoate NS/Fluticasone Propionate NSFluticasone Propionate NS/Fluticasone Furoate NSTotal
Preferred - Fluticasone Furoate Nasal Spray374986
Preferred - Fluticasone Propionate Nasal Spray171431
No Preference231437
SecondaryComparision of Mean Change From Baseline Over Treatment Periods in Daytime Reflective Total Nasal Symptom Scores (D r-TNSS) for Active Drug Nasal Sprays Versus Placebos

Reflective Total Nasal Symptom scores (rTNSS) symptoms of rhinorrhea, nasal congestion, nasal itching, sneezing using scale of: 0=none, 1=mild, 2=moderate, 3=severe.

Time frame:
Baseline, Treatment Period 1 (Days 1-7), Treatment Period 2 (Days 15-21)
Reported as:
Mean · Scores on a scale
Comparision of Mean Change From Baseline Over Treatment Periods in Daytime Reflective Total Nasal Symptom Scores (D r-TNSS) for Active Drug Nasal Sprays Versus Placebos
Scores on a scaleFluticasone Furoate NS/Fluticasone Propionate NSPlacebo - FF/FPFluticasone Propionate NS/Fluticasone Furoate NSPlacebo - FP/FF
Change from Baseline Treatment Period One-2.8 ± 0.30-1.6 ± 0.21-2.6 ± 0.26-1.7 ± 0.23
Change from Baseline Treatment Period Two-2.6 ± 0.31-2.0 ± 0.26-2.8 ± 0.28-1.9 ± 0.24
SecondaryComparision of Mean Change From Baseline Over Treatment Periods in Nighttime Reflective Total Nasal Symptom Scores (N-rTNSS) for Active Drug Nasal Sprays Versus Placebos

Reflective Total Nasal Symptom scores (rTNSS) symptoms of rhinorrhea, nasal congestion, nasal itching, sneezing using scale of: 0=none, 1=mild, 2=moderate, 3=severe; maximum score=12.

Time frame:
Baseline, Treatment Period 1 (Days 1-7), Treatment Period 2 (Days 15-21)
Reported as:
Mean · Scores on a scale
Comparision of Mean Change From Baseline Over Treatment Periods in Nighttime Reflective Total Nasal Symptom Scores (N-rTNSS) for Active Drug Nasal Sprays Versus Placebos
Scores on a scaleFluticasone Furoate NS/Fluticasone Propionate NSPlacebo - FF/FPFluticasone Propionate NS/Fluticasone Furoate NSPlacebo - FP/FF
Change From Baseline Treatment Period One-2.5 ± 0.29-1.3 ± 0.21-2.4 ± 0.26-1.6 ± 0.23
Change From Baseline Treatment Period Two-2.4 ± 0.29-1.9 ± 0.25-2.6 ± 0.30-1.6 ± 0.22

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fluticasone Furoate Nasal Spray—0/173 (0%)5/173 (2.9%)
Fluticason Propionate Nasal Spray—0/171 (0%)8/171 (4.7%)
Placebo - FF—0/176 (0%)10/176 (5.7%)
Placebo - FP—0/175 (0%)9/175 (5.1%)
Most frequent other events
Most frequent other events
EventFluticasone Furoate Nasal SprayFluticason Propionate Nasal SprayPlacebo - FFPlacebo - FP
HeadacheNervous system disorders5/1738/17110/1769/175

Baseline characteristics

Age, Continuous
Age, Continuous(years)Fluticasone Furoate NS/Fluticasone Propionate NSPlacebo - FF/FPFluticasone Propionate NS/Fluticasone Furoate NSPlacebo - FP/FFTotal
Mean37.3 ± 13.8942 ± 12.4840.5 ± 12.2939.7 ± 14.3239.9 ± 13.33
Gender
Gender(Participants)Fluticasone Furoate NS/Fluticasone Propionate NSPlacebo - FF/FPFluticasone Propionate NS/Fluticasone Furoate NSPlacebo - FP/FFTotal
Female62736760262
Male34222831115
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Fluticasone Furoate NS/Fluticasone Propionate NSPlacebo - FF/FPFluticasone Propionate NS/Fluticasone Furoate NSPlacebo - FP/FFTotal
American/African Heritage8810834
American Indian or Alaska Native00000
Asian03115
Native Hawaiian or other Pacific Islander00101
White88848280334
African American/African-American Indian/Alaskan00011
African American/African Heritage & White00112
08

Study locations

24 sites
  • GSK Investigational Site
    Scottsdale, Arizona 85251, United States
  • GSK Investigational Site
    Fresno, California 93720, United States
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
  • GSK Investigational Site
    Long Beach, California 90808, United States
  • GSK Investigational Site
    Mission Viejo, California 92691, United States
  • GSK Investigational Site
    Orange, California 92868, United States
  • GSK Investigational Site
    Miami, Florida 33176, United States
  • GSK Investigational Site
    Baltimore, Maryland 21236, United States
  • GSK Investigational Site
    North Andover, Massachusetts 01845, United States
  • GSK Investigational Site
    Jackson, Mississippi 39202, United States
  • GSK Investigational Site
    Brick, New Jersey 8724, United States
  • GSK Investigational Site
    Skillman, New Jersey 08558, United States
  • GSK Investigational Site
    Rochester, New York 14618, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27607, United States
  • GSK Investigational Site
    Charleston, South Carolina 29407, United States
  • GSK Investigational Site
    Charleston, South Carolina 29414, United States
  • GSK Investigational Site
    Mount Pleasant, South Carolina 29464, United States
  • GSK Investigational Site
    Johnson City, Tennessee 37601, United States
  • GSK Investigational Site
    Corsicana, Texas 75110, United States
  • GSK Investigational Site
    El Paso, Texas 79902, United States
  • GSK Investigational Site
    Houston, Texas 77070, United States
  • GSK Investigational Site
    Kerrville, Texas 78028, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    South Burlington, Vermont 05403, United States
09

References and documents

Publications

  • Meltzer EO, Andrews C, Journeay GE, Lim J, Prillaman BA, Garris C, Philpot E. Comparison of patient preference for sensory attributes of fluticasone furoate or fluticasone propionate in adults with seasonal allergic rhinitis: a randomized, placebo-controlled, double-blind study. Ann Allergy Asthma Immunol. 2010 Apr;104(4):331-8. doi: 10.1016/j.anai.2010.02.010. PubMed 20408344 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007, a primary completion of Nov 2007 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2009, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2007
First posted
Oct 3, 2007
Start
Aug 2007
Primary completionActual
Nov 2007
CompletionActual
Nov 2007
Results first posted
Sep 30, 2009
Last update
Dec 9, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00539006
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 3, 2007
Start date
Aug 2007
Primary completion
Nov 2007
Completion
Nov 2007
Results posted
Sep 30, 2009
Last update
Dec 9, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion